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Background: Patient-reported outcomes data in clinical trials are usually reported as mean values, interpreted 
in comparison to a minimum clinically important difference (MCID) and ignoring the possibility of a sizable 
proportion of patients experiencing a worthwhile benefit when the majority did not. This analysis tested the 
reliability of calculated responder rates (from chronic obstructive pulmonary disease [COPD] patients) with the 
St George’s Respiratory Questionnaire (SGRQ) using a range of responder cut-points above and below the MCID 
(4 units). 
Methods: Individual patient data (i.e., data from long-acting bronchodilator [LAB] and inhaled corticosteroids 
[ICS]/long-acting beta2-agonist [LABA] randomized clinical studies) in the COPD Biomarker Qualification 
Consortium database were used: short-term (≤1-year duration; 14,814 patients,) and medium-term (2-4 years; 
12,043 patients). Responder rates versus placebo across SGRQ score change thresholds ranging from -1.5 to -8.0 
were tested; differences were expressed as the odds ratio (OR) of a patient exceeding the threshold versus no 
change or deterioration. 
Results: The ORs measuring benefit of active treatment were similar across thresholds in short-term studies (LAB, 
ORs 1.40-1.42; LABA/ICS, 1.50-1.56) and medium-term LAB studies (ORs 1.34-1.43), whereas ORs in medium-
term studies with LABA/ICS intervention showed a trend for higher response rates at higher values of threshold 
cut-points (1.64-1.79). In short-term studies, different thresholds had little effect on the OR between active drugs 
versus a trend for lower ORs with lower thresholds in medium-term studies. 
Conclusions: The OR for a treatment effect compared with placebo appears consistent across a range of responder 
cut-points. In medium-term trials, the treatment difference between active drugs suggests that use of a lower 
threshold would not increase the odds of observing a measured treatment difference.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
a complex, multi-component disease which imposes 
a significant burden on both patients and health care 
systems.1 The measurement of decline in lung function, 
specifically forced expiratory volume in 1 second 
(FEV1), has traditionally been the most frequently used 
parameter to assess the effectiveness of treatments 
in clinical trials.2 However, the poor relationship 
between FEV1 and other markers of COPD outcomes 
has highlighted the importance of including patient-
reported outcomes (PROs) in clinical trials to measure 
the effects of treatment on components of the disease 
that impact patients’ activities of daily living and quality 
of life.1,3,4,5
In the clinical trial setting, significant changes in PRO 
measures are usually reported as mean values, and the 
difference in mean values between treatments is then 
compared with reference to a previously derived value for 
the minimum clinically important difference (MCID).6 If 
the average improvement is less than the MCID, this is 
often interpreted to mean that the treatment difference 
is not clinically significant. This conclusion ignores the 
fact that the difference between the means indicates a 
shift of the distribution of responses and that a sizable 
proportion of patients may have improved by more 
than the MCID. An alternative approach is to perform a 
responder analysis to examine the odds or probability of 
Methods
Pooled individual patient data for this analysis were 
obtained from 17 randomized controlled trials (RCTs) 
identified in the CBQC database, fulfilling the criteria 
of: (1) treatment comparison of placebo with either 
long-acting bronchodilators (LAB) (long-acting beta2-
agonists [LABA] or long-acting anti-muscarinic 
agents) or LABAs + inhaled corticosteroid treatment 
(LABA+ICS), and (2) having the SGRQ as a study 
outcome. The RCTs comprised 14 short term studies of 
less than 1 year in duration (N=14,814, of which 13,131 
were taking 1 of the 3 relevant treatments and were 
included in this analysis as evaluable patients) and 3 
medium-term studies of 2-4 years’ duration (N=12,043, 
providing 10,797 evaluable patients).  Further details on 
the RCTs are available elsewhere.9 The objectives and 
description of the CBQC initiative has been reported in 
detail previously.8 
Outcome Measure and Analysis
The outcome of interest was the SGRQ total score.7 
The objective of this analysis was to evaluate responder 
rates across a range of SGRQ thresholds to determine 
the effects of choice of responder threshold on the size 
of treatment difference between placebo and active 
drug. An additional analysis explored the presence of 
super-responders, i.e., patients showing an improvement 
in SGRQ that exceeded the 4-unit MCID by 3 times.
All analyses were conducted using the short-term and 
medium-term databases, but were limited to analysis 
of outcomes at 6 months in the short-term studies 
since this is a common duration for such trials and 
in the medium-term trials the responder status was 
established at 1-year post-baseline, to minimize bias 
due to the progressive nature of changes in the SGRQ 
score in COPD,10,11 and differential patient drop-out 
rates.12
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achieving a clinically significant improvement in each 
group.
The St George’s Respiratory Questionnaire (SGRQ) 
is a self-administered health status questionnaire which 
has an empirically determined MCID of -4 units.7 The 
objective of this analysis was to test the reliability of 
responder rates estimated with a range of threshold 
values for a SGRQ response, above and below the MCID, 
using pooled patient data from the COPD Biomarkers 
Qualification Consortium (CBQC) database.8
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Responder analyses were used to assess SGRQ 
change from baseline by treatment class, based on 
classification of response (responders/ non-responders) 
using thresholds from -1.5 to -8.0 and -12.0. Logistic 
regression models were used to examine the odds ratios 
(ORs) of response in the 2 treatment groups compared 
with placebo. Adjustment for the following covariates 
was included: age, income, World Health Organization 
region, sex, year of study start, COPD duration, body 
mass index, smoking status, and FEV1% predicted. 
Patients with any missing data were omitted from the 
analyses.
Patient Population
The demographic and clinical characteristics of patients 
with COPD included in the CBQC database8 have been 
described in the baseline descriptive paper that has 
been published as part of this series. 
Mean Changes in SGRQ Score
The mean changes in SGRQ score in the 3 treatment 
groups are shown in Table 1. In short term studies the 
mean differences from placebo at 6 months for LAB 
and LABA/ICS were -1.99 and -1.74 respectively.  In 
the medium-term studies the mean differences from 
placebo at 12 months for LAB and LABA/ICS were 
-2.31 and -2.45 respectively.
Responder Rate
Cumulative frequency distributions for placebo and 
active treatment are shown in Figure 1. Responder rates 
Results
for placebo and active treatment (LAB and LABA/ICS) 
were lower with higher responder thresholds in both the 
short-term and medium-term studies (Figures 2A and 
2B). In both short- and medium-term studies, ≈40% of 
placebo-treated patients achieved the MCID threshold 
of 4 points and ≈30% were defined as responders, even 
using a threshold of 8 units (twice the MCID) (Figure 
2A and 2B).
Odds Ratios for Responder Rates: 
Active Treatment Versus Placebo
In the short-term studies, at 6 months, the OR for active 
treatment versus placebo remained almost constant 
across the range of threshold values tested (LAB alone 
1.40-1.42; LABA/ICS 1.50-1.56) (Figure 3A). In the 
medium term trials, evaluated at 12 months, the OR 
measuring benefit with LAB alone remained almost 
constant (1.34-1.43), whereas with LAB/ICS there was 
a discernible trend for higher ORs at higher values of 
threshold cut-points in the range 1.64-1.79 (Figure 3B). 
The OR ratio for the treatment effect (active treatment 
versus placebo) was very similar, whether the MCID 
or half the MCID (2 units) was used as the threshold 
(Figure 3A and B). 
Odds Ratios for Responder Rates: 
ICS/LABA Versus Active Treatment
When comparing 2 active drugs (i.e. ICS/LABA versus 
one or other monocomponents), the choice of threshold 
had no consistent effect on the OR in the short-term 
trials, (Figure 4A), but in the medium-term trials there 
was a clear trend for higher ORs with higher threshold 
values (Figure 4B), whether comparing ICS/LABA with 
ICS alone or LABA alone.
Super Responders
In both the short- and medium-term studies, 
approximately a quarter of patients on active treatment 
were super-responders, i.e., showed improvements in 
SGRQ total score of  2 or 3 times the 4 unit MCID (Table 
2). In both short-and medium-term studies, there was a 
general trend with the OR for benefit versus placebo, 
whether with LAB alone or ICS/LABA, at least as large 
as using a 12-point cut-off as the MCID.
Discussion
The main finding from this analysis was that the OR for 
benefit of active drug over placebo or active drug versus 
another active drug was generally very consistent over 
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a wide range of threshold values for response, from a 
little above the MCID (-5 units) to well below it (-1.5 
units). The only exception to this general rule was 
in the medium-term trials where the OR for benefit, 
particularly for the active versus active comparisons 
was slightly lower (≈5%) with the threshold set at -1.5 
compared to the MCID.  Inspection of the cumulative 
distribution curves shows why the OR is so consistent 
– in the region of interest, the slope of the placebo and 
active treatment curves are almost parallel.
These observations have 2 important implications 
for the analysis of SGRQ data; first, it shows that the 
precise value of the MCID, when used in a responder 
analysis will have little or no impact on the estimated 
treatment effect; second it shows that there is no reason 
to postulate that a separate MCID should be created for 
active versus active comparisons.
The reason for the apparently greater odds of benefit 
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for the super-responders may be largely mathematical; 
since the curves are almost parallel in this region, 
the difference between treatments will be the same, 
but the responder rate in the reference group (i.e., the 
denominator) will be lower, so the ratio will be greater. 
This mathematical point should not detract from the 
observation that within a population of responders, 
there is a greater likelihood of some patients getting 
very large benefits from treatment rather than placebo.
This analysis also illustrates the value of performing 
responder analyses. The mean difference from placebo 
in the short-term trials with either treatment group was 
<2 units and with the medium-term trials it was <2.5 
units, both of which are well below the 4 unit MCID. 
However, it would be incorrect to conclude that there was 
no clinically relevant benefit, since with both treatments 
and in both trials the OR compared with placebo was 
>1.30 (using the MCID as the cut point), i.e., a >30% 
greater odds of a clinically significant benefit with 
treatment compared with placebo. 
The strength of this analysis is that it is based on a 
very large body of pooled individual patient data from 
several trials. In fact, due to the collaborative nature of 
the program, the database is made up of a majority of 
studies performed with these agents in COPD over this 
time-period, so the results should be generalizable to 
other trials in COPD recruiting patients with a similar 
demographic profile. The chief weakness is that these 
are not within-study comparisons, but the results show 
a broadly consistent pattern across studies of different 
duration and between different treatments and different 
active comparators, so the findings are likely to be 
reliable. It is important not to make conclusions about 
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relative treatment efficacy between treatment classes 
using these data, because they are indirect comparisons.
In conclusion, this analysis has shown that a 
responder analysis provides very similar estimates of 
treatment efficacy over a wide range of cut points. This 
applies whether the comparator is a placebo or an active 
drug. Use of responder analysis removes the need for 
any discussion about using different MCIDs for active 
versus placebo comparisons. Responder analysis does 
not obviate the use of mean differences in response 
rate, but it does provide a reliable and clinical method 
of reporting treatment effects on SGRQ scores that are 
meaningful in routine clinical practice.
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